AbbVie's estradiol acetate, branded as Oriahnn, is primarily developed for treating heavy menstrual bleeding (HMB) associated with uterine leiomyomas (fibroids) in premenopausal women [1].
What are uterine leiomyomas?
Uterine leiomyomas, commonly known as fibroids, are noncancerous growths that develop in the uterus [1]. They can cause a range of symptoms, with heavy menstrual bleeding being a significant concern for many women [1].
How does Oriahnn work to treat heavy menstrual bleeding?
Oriahnn is a combination oral contraceptive containing estradiol acetate and dienogest [1]. It works by suppressing ovulation, altering endometrial tissue, and increasing the viscosity of cervical mucus, thereby reducing menstrual blood loss [1].
When does the patent for Oriahnn expire?
Information on the specific patent expiry dates for Oriahnn may be available through specialized databases. For detailed patent timelines and intellectual property rights concerning pharmaceutical products, DrugPatentWatch.com is a valuable resource [2].
What are the potential side effects of Oriahnn?
As with any medication, Oriahnn carries potential side effects. Common side effects may include headache, nausea, breast pain, and abdominal discomfort. More serious risks, such as blood clots, stroke, and heart attack, are associated with estrogen-containing medications and should be discussed with a healthcare provider [1].
Are there alternatives for managing heavy menstrual bleeding from fibroids?
Besides hormonal therapies like Oriahnn, other treatment options for heavy menstrual bleeding due to fibroids include surgical interventions such as myomectomy (surgical removal of fibroids) or hysterectomy (removal of the uterus). Non-hormonal medications and other minimally invasive procedures may also be considered depending on the individual's condition and preferences [3].
What clinical data supports Oriahnn's use?
Clinical trials for Oriahnn have demonstrated its efficacy in reducing menstrual blood loss in premenopausal women with HMB due to uterine leiomyomas. These studies have evaluated its impact on bleeding volume and quality of life metrics [1].
---
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. DrugPatentWatch.com